INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,788,300 | -35.8% | 53,529 | -22.0% | 0.00% | 0.0% |
| Q2 2023 | $4,344,291 | +68.4% | 68,609 | +44.1% | 0.00% | 0.0% |
| Q1 2023 | $2,579,057 | +62.3% | 47,628 | +58.6% | 0.00% | – |
| Q4 2022 | $1,589,346 | +5.3% | 30,033 | -7.4% | 0.00% | – |
| Q3 2022 | $1,510,000 | -19.9% | 32,447 | -1.8% | 0.00% | -100.0% |
| Q2 2022 | $1,885,000 | -29.1% | 33,034 | -24.0% | 0.00% | 0.0% |
| Q1 2022 | $2,659,000 | -34.4% | 43,454 | -43.9% | 0.00% | 0.0% |
| Q4 2021 | $4,052,000 | +83.2% | 77,408 | +30.5% | 0.00% | – |
| Q3 2021 | $2,212,000 | -1.2% | 59,328 | +8.1% | 0.00% | – |
| Q2 2021 | $2,240,000 | +7.3% | 54,862 | -10.8% | 0.00% | – |
| Q1 2021 | $2,087,000 | -41.1% | 61,493 | -44.8% | 0.00% | -100.0% |
| Q4 2020 | $3,541,000 | +63.5% | 111,347 | +32.0% | 0.00% | 0.0% |
| Q3 2020 | $2,166,000 | +49.5% | 84,384 | -44.9% | 0.00% | – |
| Q2 2020 | $1,449,000 | +212.3% | 153,196 | +407.9% | 0.00% | – |
| Q1 2020 | $464,000 | -44.8% | 30,165 | +23.0% | 0.00% | – |
| Q4 2019 | $841,000 | +380.6% | 24,533 | +4.3% | 0.00% | – |
| Q3 2019 | $175,000 | -34.9% | 23,531 | +13.4% | 0.00% | – |
| Q2 2019 | $269,000 | -12.4% | 20,742 | -17.7% | 0.00% | – |
| Q1 2019 | $307,000 | -41.6% | 25,215 | -63.0% | 0.00% | – |
| Q4 2018 | $526,000 | -5.7% | 68,120 | +164.9% | 0.00% | – |
| Q3 2018 | $558,000 | +31.0% | 25,719 | +6.6% | 0.00% | – |
| Q2 2018 | $426,000 | -20.2% | 24,130 | -4.8% | 0.00% | – |
| Q1 2018 | $534,000 | +65.3% | 25,352 | +13.8% | 0.00% | – |
| Q4 2017 | $323,000 | -41.1% | 22,287 | -35.9% | 0.00% | – |
| Q3 2017 | $548,000 | +34.0% | 34,756 | +5.7% | 0.00% | – |
| Q2 2017 | $409,000 | -71.5% | 32,876 | -62.7% | 0.00% | – |
| Q1 2017 | $1,433,000 | +0.1% | 88,195 | -7.1% | 0.00% | -100.0% |
| Q4 2016 | $1,431,000 | +538.8% | 94,889 | +545.5% | 0.00% | – |
| Q3 2016 | $224,000 | -50.4% | 14,700 | +26.3% | 0.00% | – |
| Q2 2016 | $452,000 | +55.9% | 11,641 | +11.5% | 0.00% | – |
| Q1 2016 | $290,000 | -50.6% | 10,438 | -4.4% | 0.00% | – |
| Q4 2015 | $587,000 | +190.6% | 10,916 | +116.9% | 0.00% | – |
| Q3 2015 | $202,000 | +5.2% | 5,033 | -16.4% | 0.00% | – |
| Q2 2015 | $192,000 | -6.8% | 6,021 | -30.7% | 0.00% | – |
| Q1 2015 | $206,000 | +1371.4% | 8,686 | +995.3% | 0.00% | – |
| Q4 2014 | $14,000 | +27.3% | 793 | +0.8% | 0.00% | – |
| Q3 2014 | $11,000 | -47.6% | 787 | -35.3% | 0.00% | – |
| Q2 2014 | $21,000 | – | 1,217 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |